SEP 7, 2026 · JOURNAL ARTICLE
The Efficacy of the Dual-targeted Drug Combination Regimen Combined with TCb in Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer and Its Impact on Tumor Markers
Research in Health Science
A randomized controlled trial with a clear efficacy signal (higher ORR and pCR with dual-targeted therapy) and favorable tumor marker reduction, but with surrogate endpoints and no hard clinical outcomes reported.
Reported
Sample size112
Observation group n56
Control group n56